MERCK
24.6.2024 22:36:33 CEST | Business Wire | Press release
Merck, a leading science and technology company, today announced the discontinuation of the Phase III randomized TrilynX study evaluating xevinapant plus chemoradiotherapy (CRT) in patients with unresected locally advanced squamous cell carcinoma of the head and neck (LA SCCHN). The decision follows a pre-planned interim analysis performed by the study’s Independent Data Monitoring Committee, which found that the trial would be unlikely to meet its primary objective of prolonging event-free survival. Top-line safety data were overall compatible with the chemo-radio sensitizing properties of xevinapant. The company will conduct an in-depth review of the data and will share the results in a peer-reviewed forum.
LA SCCHN has proven to be a difficult-to-treat form of cancer. CRT has remained the standard of care for decades, despite multiple studies designed to improve outcomes with new treatment approaches, including multiple immunotherapy trials.
“We sincerely thank the patients, caregivers and clinical investigators who participated in this trial,” said Danny Bar-Zohar, Global Head of Research & Development and Chief Medical Officer for the Healthcare business sector of Merck. “While we are disappointed by these results, we remain steadfast in our commitment to develop transformative medicines within our oncology portfolio for areas of high unmet need.”
Given the totality of the data, the company decided to also stop the Phase III clinical trial X-Ray Vision (xevinapant plus radiotherapy, compared to placebo plus radiotherapy) in patients who underwent resection of locally advanced head and neck cancer.
Merck is working to develop and deliver new treatment options that exploit the vulnerabilities of tumor cells. The company is exploring modalities including antibody-drug conjugates (ADCs) and DNA damage response (DDR) inhibitors, across multiple tumor types, including many that have proven difficult to treat where there are significant unmet needs for patients. The company’s support for the head and neck cancer community remains steadfast with Erbitux®, approved in combination with radiotherapy for the initial treatment of locally advanced SCCHN, and which continues to be studied in more than 200 active clinical trials, including at least 15 Phase III studies.
About Xevinapant
Xevinapant (formerly known as Debio 1143) is an investigational potent oral small-molecule IAP (inhibitor of apoptosis protein) inhibitor. In March 2021, Merck gained exclusive rights from Debiopharm International SA to develop and commercialize xevinapant worldwide. Xevinapant is not approved for any use anywhere in the world.
Advancing the Future of Cancer Care
At Merck we strive every day to improve the futures of people living with cancer. Our research explores the full potential of promising mechanisms in cancer research, focused on synergistic approaches designed to hit cancer at its core. We are determined to maximize the impact of our standard-of-care treatments and to continue pioneering novel medicines. Our vision is to create a world where more cancer patients will become cancer survivors. Learn more at www.merckgrouponcology.com.
About Merck
Merck, a leading science and technology company, operates across life science, healthcare and electronics. Around 63,000 employees work to make a positive difference to millions of people’s lives every day by creating more joyful and sustainable ways to live. From providing products and services that accelerate drug development and manufacturing as well as discovering unique ways to treat the most challenging diseases to enabling the intelligence of devices – the company is everywhere. In 2023, Merck generated sales of € 21 billion in 65 countries.
Scientific exploration and responsible entrepreneurship have been key to Merck’s technological and scientific advances. This is how Merck has thrived since its founding in 1668. The founding family remains the majority owner of the publicly listed company. Merck holds the global rights to the Merck name and brand. The only exceptions are the United States and Canada, where the business sectors of Merck operate as MilliporeSigma in life science, EMD Serono in healthcare, and EMD Electronics in electronics.
All Merck press releases are distributed by e-mail at the same time they become available on the Merck website. Please go to www.merckgroup.com/subscribe to register online, change your selection or discontinue this service.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240624549928/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
I/ONX Shatters the Host Tax: New Symphony SixtyFour Architecture Delivers 50% TCO Savings Across AI Inference and Fine-Tuning Lifecycle22.4.2026 15:00:00 CEST | Press release
Eliminating infrastructure overhead of legacy designs, I/ONX debuts a scaled AI inference and fine-tuning stack that cuts power by up to 30kW per rack and reduces cost of rack-scale deployments by up to 70% I/ONX High Performance Compute (HPC), a leading provider of heterogeneous AI systems, today announced the global launch of the Symphony SixtyFour, a high-density platform designed to collapse the physical and economic footprint of AI inference and fine-tuning infrastructure. By supporting up to 64 accelerators on a single node, I/ONX eliminates the redundant Host Tax—the massive overhead in power, hardware, and licensing that negatively impacts ROI in enterprise AI. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260422485327/en/ I/ONX Introduces Symphony SixtyFour: The Host Tax is Over. Save 30-50% on your AI Infrastructure Costs. While inference now accounts for 90% of enterprise AI workloads, enterprises are entirely li
Thales Introduces Imperva for Google Cloud, Bringing Its Enterprise-Grade Application Security Capabilities Directly into Google Cloud22.4.2026 15:00:00 CEST | Press release
New offering eliminates the need to choose between cloud-native performance and advanced security as enterprises scale modern applications Thales today announced the Controlled Availability of Imperva for Google Cloud, bringing the industry's most trusted application security platform directly into Google Cloud. Designed to operate within Google Cloud, the new offering enables organizations to protect web applications and APIs by leveraging Google Cloud’s Service Extension traffic, preserving existing pipelines, integrations, and monitoring workflows. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260422746638/en/ ©Thales As enterprises accelerate cloud adoption, development teams increasingly standardize on native cloud services to improve speed and reduce operational complexity. Many security solutions, however, require external routing that introduces latency and friction. At the same time, native cloud security tools oft
ClickHouse Expands Strategic Collaboration with Google Cloud, Bringing Deeper Integration, Cloud Flexibility, and Next-Generation Performance22.4.2026 15:00:00 CEST | Press release
ClickHouse, a leader in real-time analytics, data warehousing, observability, and AI/ML, today at Google Next 26 announced a significant expansion of its strategic collaboration with Google Cloud. The announcement encompasses four major milestones: native integration with Google Cloud Lakehouse, the availability of ClickHouse's Bring Your Own Cloud (BYOC), the migration of ClickHouse Cloud on Google Cloud to Google's custom Arm-based Axion processors, and a new integration between the ClickHouse MCP server and Google Antigravity. These advancements deliver deeper interoperability across the data ecosystem, extend deployment flexibility for security-conscious enterprises, and unlock meaningful gains in query performance and cost efficiency for joint customers worldwide. This expansion builds on ClickHouse's growing presence within the Google Cloud ecosystem, where thousands of data-intensive organizations rely on ClickHouse Cloud to power real-time observability, business intelligence,
GigaDevice GD32F5HC Series MCU Grand Launch, Advancing High‑Performance Innovation for HMI and IoT Edge Solutions22.4.2026 15:00:00 CEST | Press release
GigaDevice, a leading global supplier of semiconductor devices, today announced the official launch of the GD32F5HC series 32‑bit general‑purpose microcontrollers. Designed with compact size, high frequency operation, large memory, and strong security, while also offering ultra‑low power consumption and rich peripheral configuration, the new series expands the GD32 Arm® Cortex®‑M33 portfolio and delivers a powerful platform for next‑generation HMI and IoT Edge solutions. Samples, development boards, and full technical documentation are now available to support rapid evaluation and mass‑production deployment. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260422790734/en/ GigaDevice GD32F5HC Series MCU for HMI and IoT Edge Solutions High‑Efficiency, Advanced Compute Performance and Integrated Security Delivering a Powerful Competitive Edge. The GD32F5HC series, built on the Arm® Cortex®‑M33 core, operates at a main frequency
Accertify Launches Global Air Travel Fraud Report Revealing Where Booking-Stage Pressure Is Most Concentrated22.4.2026 14:00:00 CEST | Press release
Q1 2026 analysis shows significant variation in prevented fraud rates by origin city, with higher concentrations across parts of Latin America, Africa, the Middle East, and South & Southeast Asia Accertify, a leading unified risk decisioning platform provider, today announced the release of its Global Air Travel Fraud Report: Q1 2026, a quarterly analysis examining how fraud risk in airline bookings varies by route origin across global markets. Based on more than 180 million airline booking transactions processed between January and March 2026, the report analyzes fraud rates by departure city as a proxy for route origin, offering airlines a practical view of where fraud prevention systems are intervening most frequently at the point of booking. The Q1 2026 findings show that fraud risk in airline bookings is unevenly distributed across markets, with meaningful differences emerging by region and by origin city. Routes originating in North America and Australia continue to exhibit consi
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom